Our results also imply that recommendation of full screening of the BRCA1 and BRCA2 genes, and even additional predisposing genes, to all breast cancer patients should remain the ultimate goal as new technologies emerge that can lower the cost and effort involved. The gene discussed is BRCA1; the disease is breast cancer.